indb
|
|
|
- 男耳 齐
- 9 years ago
- Views:
Transcription
1
2 TM CHINA PIONEER PHARMA HOLDINGS LIMITED 333,334,000 33,334, ,000, %0.003% 0.005% C %0.003% 0.005%
3 ( 1 ) eipo (2) (3) (4) eipo (5) (6) (7) (1) i
4 ( 1 ) (2) (3) 10. (4) 6. (5) (6) (7) ii
5 i iii I II III IV V-1 iii
6 17 Frost & Sullivan 9.4% % 27.1% 33.8% 36.3% % 53.7% 66.0% 65.2%55.0% 54.0% 62.6% 53.1% % 72.9% 66.2% 63.7% % 46.3% 34.0% 34.8% 1
7 ,589 1, %) 2, % 17,83985,420 Frost & Sullivan Frost & Sullivan 8% 55.2% 86.4% 2
8 Frost & Sullivan 14% 17.6% 22.0% % 80.6% 84.6% 79.7% 79.6% 97.1% 96.7% 94.5% 92.2% 65.4% 61.1% 60.1% 59.1% 19.9% 17.6% 17.5% 16.4% 5.7% 4.1% 4.3% 4.0%
9 % % %29.1% 27.3% 32.0% % %29.6% % 13.2% 13.5% 19.4% % % 20.1% (i) (ii)
10 5
11 % % % % % , , , , , (1) , , , , , , , , , , , , , , , (1) , , , , , , , , , , , , , , , (1) , , , , , , , , , ,
12 % % % % % (1) (1) Frost & Sullivan % 21.1% 1, % 20.5% 1,770 Frost & Sullivan 40.0% 21.8% 22.6% % 18.4% % 9.4% % 7.7% % 5.0% % 4.1% Frost & Sullivan 7
13 8
14 , , , , , (404,557) (70.9) (522,129) (72.7) (651,978) (68.0) (299,265) (69.2) (388,097) (70.4) , , , , , , , , , , , , (3,347) (0.8) (7,091) (1.3) (63,811) (11.2) (68,652) (9.6) (92,087) (9.6) (41,375) (9.5) (47,740) (8.6) (7,440) (1.3) (15,565) (2.7) (18,333) (2.5) (28,670) (3.0) (11,681) (2.7) (13,596) (2.5) (4,976) (0.8) (5,490) (0.8) (9,435) (1.0) (4,805) (1.1) (3,820) (0.7) (1,160) (0.2) , , , , , (21,805) (3.8) (26,081) (3.6) (21,122) (2.2) (9,194) (2.1) (13,842) (2.6) , , , , ,
15 ,085 29,488 61,579 82, , , , , , , ,553 1,049, , , ,728 1,043, , , ,728 1,044, , , ,825 5, , , ,533 1,049, ,205 (21,777) 120,758 41, , ,912 (147,341) (27,498) (41,643) (25,729) (84,642) 106,334 (85,082) 2,694 (97,574) ,475 (62,784) 8,178 2,778 36, , ,336 51,356 51,356 59, (196) ,336 51,356 59,559 54,743 96, Pioneer Pharma (BVI) 10
16 % % % % % , , , , , , , , , , , , , , , , , , , , , , Zenotec , , , , , , , , , , , , , , , , , , , , , , , , , , , , GSP GMP 11
17 % 71.1% 68.7% 66.4% % 22.3% 24.0% 21.3% % % % 29.1% 27.3% 32.0% % % 29.6% 12
18 33,334,000 S 300,000,000 25% 28.8% (1) , ,666.7 (2) (1) 1,333,334,000 (2) 1,333,334,000 30% 13
19 , % % % % % %
20 Pioneer Pharma (BVI) 75.0% Pioneer Pharma (BVI) 48.5%3.0% Pioneer Pharma (BVI) 15
21 AMG amg International GmbH Q Asian Strategic Alliance Partners... Asian Strategic Alliance Partners Pte. Ltd. Choe Siaw Lai Catherine Janet Shung Suk Ling 60% 35% 5% Choe Siaw Lai Catherine Janet Shung Suk Ling
22 A Pioneer Pharma (BVI) Covex Covex, S.A. Covex 24% 17
23 Frost & Sullivan.. Frost & Sullivan Grand Hill Technology Grand Hill Technology Limited Tam Wai Ming..... eipo
24 33,334, ,000, S 144A
25 UBS AG... UBS AG Pioneer Pharma (BVI) 20
26 Pioneer Medident Pioneer Medident Grand Hill Technology NovaBay NovaBay Pharmaceuticals, Inc. NovaCal Pharmaceuticals, Inc. NovaCal Pharmaceuticals, Inc. NovaBay Pharmaceuticals, Inc. NovaBay 5.2% %0.003% 0.005% 21
27 Pioneer Pharma (BVI) ,000,000 15% % Pioneer Medident.... Pioneer Medident (SE Asia) Pte. Ltd. 60% Pioneer Pharma (BVI).. Pioneer Pharma (BVI) Co., Ltd % 22
28 Q Q3 Medical Devices Limited Q3 21.2% A QualiMed QualiMed Innovative Medizinprodukte GmbH Q3 S S A A
29 Li Yanming % UBS AG UBS AG Pioneer Pharma (BVI)
30 eipo eipo eipo
31 510(k) US Federal Food, Drug, and Cosmetic Act510(k) 90 USFDA510(k)
32 T COPD
33 CRO GMP
34 GSP
35 %
36 USFDA
37 32
38 571V 33
39 97.1% 96.7% 94.5% 92.2% Polichem 80.9% 78.7% 34
40 % 72.9% 66.2% 63.7% % 46.3% 34.0% 34.8% 18.0% 17.3%16.4% 16.2% 35
41 % 71.1% 68.7% 66.4% % 22.3% 24.0% 21.3%
42 967 37
43 500 38
44 (GSP) 2.8% 17.7% 16.5% 14.3% 13.0% 10.7% 9.4% 7.3% 7.3% 4.4% 4.9% 4.7% 4.7% 2.8% 3.2% 2.4% 3.0% 39
45 68.7% 66.4% 40
46
47 NovaBay QualiMed Q
48 (i) (ii) (iii) (iv)
49 44
50 % % 45
51 [2008]78 15% [2011]114 15% [2012] %40% 15% 9% 9%15% 46
52 [2008]62 [2011]52 200, ,00015% 50% Frost & Sullivan 47
53 48
54 49
55 50
56 10% 10% 51
57 10% 50% 25% (i)(ii) (iii) (iv) 25% 52
58 53
59 75.0%
60 A (1) (a) 55
61 (b) 159 (c) (1) (2) (2) 56
62 ,334,000 33,334, ,000, ,334,000 50,000, Pioneer Pharma (BVI) % 0.003% 0.005% ,000, ,000, ,333,334, % % 0.2% 57
63
64 A A A 2 59
65 8 42 UBS AG 8 52 UBS AG Walkers
66
67 190 Elgin Avenue George Town Grand Cayman KY Cayman Islands
68 Intertrust Corporate Services (Cayman) Limited 190 Elgin Avenue, George Town Grand Cayman KY Cayman Islands
69
70 (i) (ii) 65
71 GSP GSP GSP GSP GSP GSP 66
72 GSP GSP 10,000 10,000 30,000 67
73
74 (1) (2) (3)
75 70
76 115%125% 71
77 72
78 73
79 74
80 5, , % 75
81 5% 10,000 50,
82 10% 50%
83 (1) (2) (3) (1) (2) (3) 78
84 75 Pioneer Pharma (BVI) 25% 15% 25% 79
85 10% 10% 15% 70% 15% [2012] %40% 15% 9%9% 15% [2008]62 26 [2011]
86 (i)(ii) (iii) 5% 17% [2008]62 [2011]52 200, ,000 15% 50% 25%5% 25%10% 81
87 (1) (2) (3) (1) 12.5%(2)
88 Frost & Sullivan Frost & Sullivan 314, , %10.1% Frost & Sullivan 577, , % 23,708 38, % Frost & Sullivan 42,414 64, % 83
89 100,000 80,000 60,000 40,000 20,000 64,219 57,716 47,156 51,932 40,151 31,405 34,090 35,083 38,35442,414 23,70825,608 30,015 71,764 52,218 46,960 80,156 89,575 64,536 58,036 80,000 60,000 40,000 20, Frost & Sullivan Frost & Sullivan 15,781 24, % 28,100 46, % 4,761 7, % 9,132 15, % % %
90 Frost & Sullivan 3,000 2, ,500 2,000 1,500 1, Frost & Sullivan 26.3% 284 % , ,503 8, ,161 4, ,865 4, ,541 4,958 (3.6) ,034 3,630 (3.5) , ,598 3,437 (1.5) ,760 5, ,768 3,010 (7.2) Frost & Sullivan 85
91 5.2% 11.6% 17.9% (%) Frost & Sullivan 14,540 28, % Frost & Sullivan 12.5% 53,670 6,000 5,367 5,000 4,000 3,000 2,000 1,454 1,754 1,998 2,436 2,891 3,351 3,763 4,290 4,792 1,000 0 Frost & Sullivan 86
92 ( ) 8,500 3,318 15,228 4,506 ( ) 8, %0.02% 87
93 6.5% 7.0% % 88
94 23, % 91% 15% 5% 80% 91% 9% Frost & Sullivan 1,6246,5665,962 Frost & Sullivan 3,4218, % 20, % 89
95 2,500 2,000 1,708 2,015 1,500 1, ,022 1,216 1,447 0 Frost & Sullivan Frost & Sullivan % Frost & Sullivan 1, % 90
96 Frost & Sullivan Frost & Sullivan 122Frost & Sullivan % % % %
97 Frost & Sullivan Frost & Sullivan 92
98 Frost & Sullivan 2,2144, %12, % 14,000 12,201 12,000 10,245 10,000 8,576 8,000 7,101 6,000 4,000 2,000 2,214 2,678 3,265 3,966 4,815 5,872 0 Frost & Sullivan Frost & Sullivan 50% 16.2% 93
99 Frost & Sullivan 8962, % 6, % Frost & Sullivan 94
100 Frost & Sullivan % 1, % Frost & Sullivan Frost & Sullivan % % % %
101 Frost & Sullivan Frost & Sullivan 96
102 Frost & Sullivan 2,509 9, % Frost & Sullivan 37, % 97
103 40,000 37,526 35,000 30,000 28,866 25,000 21,868 20,000 15,000 10,000 5,000 2,509 4,054 5,611 7,764 9,654 12,647 16,567 0 Frost & Sullivan Frost & Sullivan 8.7% 9.4% 98
104 % 18.4% % 9.4% % 7.7% % 5.0% % 4.1% Frost & Sullivan Frost & Sullivan Frost & Sullivan Frost & Sullivan720,000 Frost & Sullivan Frost & Sullivan 99
105 Frost & Sullivan Frost & Sullivan Frost & Sullivan Frost & Sullivan Frost & Sullivan Frost & Sullivan 100
106 Klinge Pharma GmbH (Alfa Wassermann) 100 NovaBay 101
107 NovaBay QualiMed AMGQ %0.4 20% (i) 60% 40% 99.9% (ii)0.1% 95.1% 4.9% 100% 102
108 % 65% 4 70%20% 10% 11 Pioneer Medident Pioneer Medident 66 Pioneer Medident Asian Strategic Alliance Partners 44 Pioneer Medident 103
109 Asian Strategic Alliance Partners 1 199,99479,996 Pioneer Medident Pioneer Medident 60% Asian Strategic Alliance Partners 40% Pioneer Medident 1 1,000,0001 Asian Strategic Alliance Partners Grand Hill Technology 1 600,000200, ,000 60% Asian Strategic Alliance Partners 20% Grand Hill Technology 20% NovaBay NovaBay NovaBay NovaBay NovaBay NovaBay NovaBay 2.5 2,000,000 NovaBay (a) NovaBay (b) 1.50 NovaBay NovaBay NovaBay NovaBay NovaBay NovaBay NovaBay NovaBay NovaBay NovaBay NovaBay 5,656 NovaBay 104
110 2,005,656 NovaBay NovaBay 38,796,5292,000,000 NovaBay NovaBay 5.2% NovaBay 2,000,000 NovaBay 3 NovaBay 10% NovaBay 38,796,529 Q3 QualiMed QualiMed TsunaMed QualiMed QualiMed Q3 QualiMed Q3AMG QualiMed AMG 1.8Q33.2 Q3 38, ,000 19,284 Q3150,000 1 Q3 Q3 700,000 QualiMedQ3 7,254 Q3 3.5% Q3 45,824 Q3 22.1%Q3 21.2% Q3 (i) Q31.0 Q3 1 Q3 105
111 10% Q3Q3 (ii) Q31.5 Q3 1.5 Q310% Q3Q3 Q3 Q329.0% Q3 Covex Covex Covex Covex Covex Covex Covex Covex 224% Covex 24% Covex 24% Covex Covex 14A Covex Covex Covex Covex Covex 24% Covex 106
112 Covex Covex (i) Covex NovaBay QualiMed Q3 (ii) Covex NovaBay QualiMed (iii) NovaBay QualiMed Mathijs van Basten Batenburg Batenburg (iv) NovaBay Q3 QualiMed NovaBay Q3 QualiMed (v) NovaBay Q3 NovaBay Q3 Covex Covex Mavens Covex Covex Mavens 107
113 (1) 40% 60% 100% (2) (3) 99.9% 0.1% 100% 35% 100% 70% 24% 65% (4) Covex (5) 60% 60% 5.4% Pioneer Medident (6) (7) NovaBay(8) (1) 100% (2) (3) (4) 30% 20% 10% (5) Covex (6) Pioneer Medident 40% Asian Strategic Alliance Partners Asian Strategic Alliance Partners Choe Siaw Lai Catherine Janet Shung Suk Ling 60% 35% 5% Choe Siaw Lai Catherine Janet Shung Suk Ling (7) 40% 20% Asian Strategic Alliance Partners 20% Grand Hill Technology Grand Hill Technology Tam Wai Ming 50% Tam Wai Ming 108
114 (8) NovaBay NovaBay 120,000NovaBay NovaBay Pioneer Pharma (BVI) Pioneer Pharma (BVI) 55,000, Pioneer Pharma (BVI) Pioneer Pharma (BVI) Pioneer Pharma (BVI) 500,500 Pioneer Pharma (BVI) 1,999,499 Pioneer Pharma (BVI) 5 75,000 Pioneer Pharma (BVI) 1.5% 9.0 Pioneer Pharma (BVI) 3% Pioneer Pharma (BVI) Pioneer Pharma (BVI) Pioneer Pharma (BVI) 5500,000, Pioneer Pharma (BVI Pioneer Pharma (BVI) 99 Pioneer Pharma (BVI) Pioneer Pharma (BVI) 100,100,000 Pioneer Pharma (BVI) 399,899,
115 55,000, ,001,000 1,001,000 3,998, ,210, % 19,690,000 35% 300,000 70% 110
116 70% 20% 10% 210, % 3.7% 6.6% 7.9% ,843,105 7,743,600 60% Pioneer Medident 60% NovaBay Q3 111
117 60% 10% 112
118 (1) 48.5% 48.5% 3.0% Pioneer Pharma (BVI) 100% 100% 100% 100% 100% 60% 60% 5.2% 21.2% (2) Pioneer NovaBay (4) Q3 (5) Medident (3) 100% 70% 60% (6) (7) (1) (2) 40% Asian Strategic Alliance Partners 20% Grand Hill Technology 20% Asian Strategic Alliance Partners Choe Siaw Lai Catherine Janet Shung Suk Ling 60% 35% 5%Choe Siaw Lai Catherine Janet Shung Suk Ling Grand Hill Technology Tam Wai Ming 50% Tam Wai Ming (3) Pioneer Medident 40% Asian Strategic Alliance Partners (4) NovaBay NovaBay10%NovaBay NovaBay 120,000NovaBay NovaBay 113
119 (5) QualiMed AMGQ3 Q3 4.0% Q3 4.7% (6) 30%20% 10% (7) 40% 10% (1) 48.5% 48.5% 3.0% Pioneer Pharma (BVI) 75.0% 25.0% 100% 100% 100% 100% 60% 60% 5.2% 21.2% Pioneer NovaBay (4) Q3 (5) Medident (3) (2) 100% 70% 60% (6) (7) (1) 114
120 (2) 40% Asian Strategic Alliance Partners 20% Grand Hill Technology 20% Asian Strategic Alliance Partners Choe Siaw Lai Catherine Janet Shung Suk Ling 60% 35% 5%Choe Siaw Lai Catherine Janet Shung Suk Ling Grand Hill Technology Tam Wai Ming 50% Tam Wai Ming (3) Pioneer Medident 40% Asian Strategic Alliance Partners (4) NovaBay NovaBay10%NovaBay NovaBay 120,000NovaBay NovaBay (5) QualiMed AMGQ3 Q3 4.0%Q3 4.7% (6) 30%20% 10% (7) 40% 10% (i)(ii) (iii) Pioneer Pharma (BVI) Pioneer Pharma (BVI) 75 Pioneer Pharma (BVI) 115
121 17 Frost & Sullivan 9.4% % 27.1% 33.8% 36.3% % 53.7% 66.0% 65.2%55.0% 54.0% 62.6% 53.1% % 72.9% 66.2% 63.7% % 46.3% 34.0% 34.8%
122 3121,5891, %) 2, %17,83985, Frost & Sullivan Frost & Sullivan 8% 55.2% 86.4% Frost & Sullivan 14% 17.6% 22.0% % 80.6% 117
123 84.6% 79.7% 79.6% 97.1% 96.7% 94.5% 92.2% 65.4% 61.1% 60.1% 59.1% 19.9% 17.6% 17.5% 16.4% 5.7% 4.1% 4.3% 4.0% % % %29.1% 27.3% 32.0% % %29.6% % 13.2% 13.5% 19.4% % % 20.1% 118
124 Frost & Sullivan 9.4% Frost & Sullivan 3121,5891, %) 2, %17,839 85,420 1,200 Frost & Sullivan % 119
125 21.1% 1, % 20.5% 1,770 Frost & Sullivan 40.0% 21.8% 22.6% Frost & Sullivan Frost & Sullivan 8% 55.2% 86.4% Frost & Sullivan 14% 17.6% 22.0% 120
126 % 57.3%13.2% 19.4% 20.1% 17 Frost & Sullivan 121
127 16 100%
128 ,5891, %) 2, %17,839 85, ,
129
130 NovaBay NovaBay 2.5 QualiMed TsunaMed TsunaMed 1.8 QualiMed Q Asian Strategic Alliance Partners Pioneer Medident 5% (ERP) ERP ERP 125
131 GSP ERP (i) (ii) 126
132 127
133 % % % % % , , , , , (1) , , , , , , , , , , , , , , , (1) , , , , , , , , , , , , , , , (1) , , , , , , , , , ,
134 % % % % % (1) (1) 129
135 (CRO) CROCROCRO CRO CRO CRO CRO
136 GSP GSP 3121,5891, %) 2, %17,83985, ,010 1,068 1,092 1, ,361 2,569 2,636 2, ,273 6,761 10,348 17, ,411 52,471 79,004 85,420 1,
137 132
138 133
139 134
140 135
141 31500 GSP GSP 1,100 5% % 136
142
143 (i) 10.2% 5.6% 5.3% (ii) (iii) 0.84% 1.23% 0.004% 138
144
145
146 CROs NovaBay QualiMed % % % % % , , , , , , , , , , , , , , , , , , , , , , Zenotec , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
147 H H H H H H H H Polichem H Polichem H H
148 Covex H Zenotec 20 H (1) H (1) H H H H H H (2) H H H H H H H H H H H H (1) (1) (2) (1) H % 16.5% 14.3% 13.0%10.7% 9.4% 7.3% 7.3% H % 4.9% 4.7% 4.7%2.8% 3.2% 2.4% 3.0% (2) (i) (ii) 1% 0.6% 0.5% 0.5% 0.6% 0.4% 0.2% 0.2% 143
149 Frost & Sullivan 15.5% % , % % 57.9 Frost & Sullivan Frost & Sullivan 24.4%1, % % %
150 Frost & Sullivan 14.5% 2, % Cardinal Health (H.K. Co. Limited Frost & Sullivan 44.3% 1, Polichem 145
151 Polichem (Italian Health Authority) Frost & Sullivan 12.1%739 13% Polichem S.A Polichem Polichem Polichem Polichem Frost & Sullivan 11.5%160 19% Polichem Covex 146
152 Frost & Sullivan 23.8% 5.7% Covex Covex % 14.2 Zenotec Zenotec Zenotec Zenotec Zenotec Zenotec Frost & Sullivan , % %
153 14,000 23,000 5 Frost & Sullivan 11.2% 16,000 34, NovaBay 5.5 CollaGuard Innocoll Ethypharm
154 Magma Archimedes QualiMed Pharmascience STARflo istar 0.01% NovaBay NovaBay USFDA 510(k) Frost & Sullivan 5020% NovaBay 5.5 NovaBay NovaBay 5.2%2.5 NovaBay NovaBay NovaBay NovaBay 149
155 CollaGUARD CollaGUARD Frost & Sullivan 21 15% Innocoll Pharmaceuticals Limited CollaGUARD CollaGUARD CollaGUARD Frost & Sullivan 2 10% Ehypharm Shanghai Ethypharm Pharmaceutical Co., Ltd. AstraZeneca Frost & Sullivan 4 30% Magma QualiMed Magma 150
156 Magma Frost & Sullivan Frost & Sullivan 45 20% QualiMed Magma Magma QualiMed QualiMed QualiMed QualiMed NovaBay QualiMed Archimedes QualiMed archimedes archimedes Frost & Sullivan 80 10% QualiMed Archimedes archimedes Frost & Sullivan % Pharmascience Inc. 151
157 STARflo STARflo Healionics STAR STARflo STARflo STARflo Frost & Sullivan Frost & Sullivan 8 30% istar Medical STARflo STARflo GMP
158 % 71.1% 68.7% 66.4% % 22.3% 24.0% 21.3% % 15.6% 14.0% 16.4% 1.8% 12.0% 9.1% 9.8%6.1% 4.5% 5.1% 6.4% 15.0% 2.4% % 50.3% 48.2%18.2% 7.9% % 153
159 % % 29.1% 27.3% 32.0% % % 29.6% 154
160 /12/ /12/2019 (1) 31/12/2013 (2) 31/1/ /12/2017 Polichem (3) 30/12/2014 Covex /7/ Zenotec 29/3/2017 CB Fleet /12/2015 (1) (2) (3) Skytec International Pty Ltd. Polichem Skytec Polichem 6 155
161 % 96.7% 94.5% 92.2% 5% Covex Covex Covex 80.6% 84.6% 79.7% 79.6% % 72.9% 66.2% 63.7% % 46.3% 34.0% 34.8% (i) (ii)
162 (i) GSP (ii) 157
163 Covex NovaBay Q3 Covex NovaBay Q % 90.1% 91.2% 91.2%
164 % 0.6% 0.1% 0.2% % 17.6% 17.5% 16.4% 5.7% 4.1% 4.3% 4.0% 5% 159
165 Frost & Sullivan GSP 160
166 GSP
167 ,000 50,000 5,000
168 , % 50, ,350,000
169 164
170 3,269 17,179 2,296 1, %15% 5 32L6(2) 342(1)(b)34(2) 165
171 IIIII X 166
172 II III X II III X II III 167
173 Pioneer Pharma (BVI) 75.0% Pioneer Pharma (BVI) 48.5%3.0%Pioneer Pharma (BVI) 99.9% 60% 40% Covex 24% Covex Covex Covex Covex Covex Covex 24% Covex Covex 168
174 Covex Covex Covex Covex Covex Covex 0.2% 1.8% 4.0%1.1% 0.7% 1.3% 4.9% Covex Covex Mavens Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex CovexCovex Covex Covex Covex Covex Covex Covex Covex 169
175 Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex Covex NovaBay NovaBay 2,005,656 NovaBay NovaBay 5.2% 120,000 NovaBay 3 NovaBay 2,000,000 NovaBay 10% NovaBay NovaBay NovaBay 170
176 Covex Covex 24% Covex Covex Covex Covex 24%Covex Covex Covex
177 50,000 (5)
178 (a) (b) (i) 10%(ii) 5% (a) (b) (c) (i) 173
179 (ii)30 60 (d) (a) (b) 14A 174
180 14A 1. Pioneer Medident Pioneer Medident A.65(4) % 14A.31(2) 2. 30,000 30,000 60,
181 14A.65(4) % 14A.31(2) 3. 3, % 14A.33(3) ,000 C
182 1, % 14A.33(3) 5. 60% 40% , , % 14A.33(3)
183 5 2 14A A 178
184 Pioneer Medident NovaBay 5.2% NovaBay NovaBay 179
185 42 Pioneer Medident UBS AG 180
186 (University of the Manchester) (Manchester Business School) (University of Kent) 181
187 13.51(2)(a) (v)
188 L Occitane International S.A
189 A ,000755, ,000252,
190 1,250,000 1,714,0002,041,0001,385, ,000 3A.19 3A.23 (i) (ii) (iii) (iv) 185
191 XV2 3 10% Pioneer Pharma (BVI) ,000,000,000 (2) ,000,000,000 (3) ,000,000,000 (1) 75.0% 75.0% 75.0% (1) (2) Pioneer Pharma (BVI) 48.5% 48.5% (3) Pioneer Pharma (BVI) 48.5% 48.5% XV2 3 10% 186
192 ,000,000, ,000, ,000, ,000, ,000, ,000, ,000, ,000, ,334, ,333, ,333,334, ,333,340 (a) (b) 187
193 (c) (i) 20% (ii) (1) (2) (3) 3. 10% A. 7. (i) (ii) (iii)
194 17 Frost & Sullivan 9.4% % 27.1% 33.8% 36.3% % 53.7% 66.0% 65.2%55.0% 54.0% 62.6% 53.1% % 72.9% 66.2% 63.7% 189
195 % 46.3% 34.0% 34.8% ,5891, %) 2, %17,83985, Frost & Sullivan Frost & Sullivan 8% 190
196 55.2% 86.4% Frost & Sullivan 14% 17.6% 22.0% % 80.6% 84.6% 79.7% 79.6% 97.1% 96.7% 94.5% 92.2% 65.4% 61.1% 60.1% 59.1% 19.9% 17.6% 17.5% 16.4% 5.7% 4.1% 4.3% 4.0%
197 % % %29.1% 27.3% 32.0% % %29.6% % 13.2% 13.5% 19.4% % % 20.1% Frost & Sullivan % 21.1%1, % 20.5%1,
198 Frost & Sullivan 21.8% % 72.9% 66.2% 63.7% 43.5% 46.3% 34.0% 34.8%
199 31 20, % 71.1% 68.7% 66.4% % 22.3% 24.0% 21.3%
200 , , , , , , , , , , , , , , ,
201 29.9% 27.1% 33.8% 36.3%56.5% 53.7% 66.0% 65.2% 70.1% 72.9% 66.2% 63.7%43.5% 46.3% 34.0% 34.8% 25% 22% 24% 25% 15% 9% 22.5% 21.2% 10.2% 11.1% 9% 196
202 9% (i) (ii) Covex (iii) Covex Covex 197
203
204
205 6 200
206 201
207 202
208 203
209 , , , , , , , , , , , , , , , % 72.9% 66.2% 63.7% 204
210 (i) (ii) (iii) 205
211 ... 76, , , , , , , , , , , , , , , , % 105, % 202, % 85, % 106, % , % 90, % 104, % 47, % 56, % , % 195, % 306, % 133, % 163, % 206
212 55.0% 54.0% 62.6% 53.1% 54.0%62.6% (i) (ii) (iii) 62.9%53.1% 18.0% 17.3%16.4% 16.2% ,937 7,269 11,383 5,337 35, ,827 7,455 14,428 9,355 6, ,453 15,944 26,604 15,073 42,
213 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
214 , , , , , , , , , , , , , , , , , , , , , , , , , , , , % Pioneer Medident 17% 209
215 25% 22% 24% 25% 15% 9% i ii iii 15%40% 9% 9% ,963 26,855 24,978 12,794 12, ,963 27,375 24,978 12,794 12, (2,540) (2,540) (2,158) (1,294) (2,002) (1,746) ,805 26,081 21,122 9,194 13,842 5% 10% 210
216 , , , , , (404,557) (70.9) (522,129) (72.7) (651,978) (68.0) (299,265) (69.2) (388,097) (70.4) , , , , , , , , , , , , (3,347) (0.8) (7,091) (1.3) (63,811) (11.2) (68,652) (9.6) (92,087) (9.6) (41,375) (9.5) (47,740) (8.6) (7,440) (1.3) (15,565) (2.7) (18,333) (2.5) (28,670) (3.0) (11,681) (2.7) (13,596) (2.5) (4,976) (0.8) (5,490) (0.8) (9,435) (1.0) (4,805) (1.1) (3,820) (0.7) (1,160) (0.2) , , , , , (21,805) (3.8) (26,081) (3.6) (21,122) (2.2) (9,194) (2.1) (13,842) (2.6) , , , , , (62) (3,243) (0.4) 3, (62) (2,627) (0.3) , , , , , , , , , , , , , (652) (0.1) (343) (0.1) (1,419) (0.3) 75, , , , , , , , , , , , (652) (0.1) (343) (0.1) (1,419) (0.2) 75, , , , , % % (i) 211
217 (ii) (iii) % % % % % % 29.6% 62.9% 53.1% 47.4% 36.3% 31.4% 16.1% 16.2%
218 % % 8.6% % % 2.5% % % % 11.1% % % 20.1% 213
219 % %323.7(i) (ii) (iii)(iv) % % % % % %32.0% 66.5%33.8% 27.1% 54.0%62.6%(i) (ii) (iii) 17.3% 16.4% %
220 % 92.1 (i) (ii) % 9.5% % 28.7 (i) (ii) (iii) 2.5% 3.0% % % % 10.2% 9% % % 19.4% %
221 %194.4 (i) (ii) % % % % % %27.3% 30.8%72.9%70.1% 55.0% 54.0% 18.0%17.3% % % 68.7 (i) (ii) %9.6% 216
222 % 18.3 (i) (ii) 2.7%2.5% % 5.5 (i) (ii) % % 21.2% 15% % %13.5% ,205 (21,777) 120,758 41, , ,912 (147,341) (27,498) (41,643) (25,729) (84,642) 106,334 (85,082) 2,694 (97,574) ,475 (62,784) 8,178 2,778 36, , ,336 51,356 51,356 59, (196) ,336 51,356 59,559 54,743 96,
223 (i)64.0 (ii)9.3(i) 20.6(ii) (i)56.3 (ii) (i)135.3(ii) (i) (ii) (iii) (iv) (i)18.0(ii)
224 Q3 QualiMed NovaBay 11.7 NovaBay
225 , , , , , ,323 2,829 2, , , , , , ,646 28, , ,221 2, , , , , , ,470 5,300 11, ,336 51,356 59,559 96,141 62, , , , , , , , , , , , , ,077 9,894 3,823 2, , , , , , ,548 1,952 1,162 3,890 3, ,909 2,797 3,223 3,685 3, ,801 9, , , ,728 1,043,839 1,000, , , ,246 (76,639) (42,130) , , , , (956) (247) (73) , , , ,
226 (1) (2) (3) (1) (2) (3) (i) (ii) (iii)(iv)
227 ,619 97, , , (424) (543) (107) (324) 78,195 97, , , ,632 37,826 55,988 36, ,841 2,269 4,531 6, (260) (122) (136) (46) ,454 3,655 6,156 6, ,042 7,223 3,864 5, ,148 7,567 1, , , , ,159 (1) (1) % 0.6% 0.1% 0.2% 222
228 ,191 83, , , ,855 12,670 15,080 31, ,321 3, ,195 97, , , % , , , , ,576 3,393 2, ,593 2,897 15,841 4, ,744 5,201 2,166 12, ,289 10,453 9,094 17, ,779 1,919 2, , ,038 4,731 5, , , ,580 8,248 6,609 4, , , , ,
229 (1) (1) , , , , ,866 44,451 48,326 66, , , , , , , , , , , , , ,784 25, , , , ,
230 1.79% 3.36% 3.28% 6.70% 1.26% 6.90% 1.20% 6.90% % 42.9% 44.8% 42.5% ,339 1, , ,780 11, ,339 4,707 12,466 6,
231 %) % 31% (1)..... (2) x 100% 52.3% 92.2% 206.3%... (2) x 100% 14.8% 21.6% 22.5% (3)... (4) x 100% (55.3%) (4.2%) 23.5% n.m. (1) 52.3% 92.2% 91.4% 10.6% (2) (3) (4) 226
232 % 84.6% 79.7% 79.6% 227
233 , ,987 1,204 44, ,661 64,623 67,081 49, , ,659 15,792 24,987 9, ,512 1, , ,405 27,508 47, ,320 80,482 92,254 64,257 5% 5% 5% ,062 1,711 2, % 232,391,000256,224,000335,335,000 5% 228
234 8,715,000 9,608,00012,575,000 6% 7% 5% 5%24% 24% 17% 19%
235 633,000543,000128,000 (1) (2) (3)(5) (9,525) 1,025,290 1,015, (9,525) 1,255,108 1,245, (1) (2) 333,334,
236 (3) 2 1,333,334,000 (4) (5) %
237 Pioneer Pharma (BVI) 232
238 , % (i) (ii) (iii) (iv) 15% % % (i) (ii) 15% %
239 1, ,
240 UBS AG 33,334,000 (i) (ii) (a) (i) (ii) 235
241 (iii) (iv) (v) (vi) (vii) (viii) (ix) 236
242 (x) (xi) (xii) (xiii) (xiv) (xv) (xvi) (1) (2) (3) (4) (b) (i) 237
243 (ii) (iii) (iv) (v) (vi) (vii) (viii) (A)
244 10.08 (B) 10.07(1)(a)(i) Pioneer Pharma (BVI) (ii) (a) (b) (a) (a) 10.07(2) (2) 10.07(2) (3) (a) (b) 10.07(2) (2) 239
245 (A) (a) (b) (c) (d) (a) (b) (a) (b) (c) (a) (b) (c) (a) (b) (c) 240
246 (B) (a) (i) (ii) (iii) (iv) (i) (ii) (i) (ii) (iii) (i) (ii) (iii) (b) (c) (a)(i) (ii) (iii) (a)(i) (ii) (iii) 241
247 (i) (ii) 3% 1.5% 1.5% 242
248 30 50,000,000 15%1%0.003% 0.005% A
249 (a) (b) 244
250 UBS AG (a) (b) 33,334,000 S 300,000, % 28.8% 33,334,00010% 2.5% 5 245
251 5 33,334,000 50%16,667,000 33,334,000 10% (i)1550(ii)50100 (iii) ,002,000(i) 133,334,000(ii) 166,668,000 (iii)30% 40% 50% 246
252 300,000,000 90% 22.5% S 144A 30 50,000,000 15% 247
253 50,000,000 15% 30 50,000,000 15% Pioneer Pharma (BVI) 50,000,000 (a) (b)(i) (ii) (iii) (i) (ii) (iv) (v)(ii) (iii) (iv) 248
254 30 Pioneer Pharma (BVI) 10.07(3) 10.07(1)(a)(i) (ii) Pioneer Pharma (BVI) Pioneer Pharma (BVI)
255 %0.005% 0.003%1,000 5,
256
257 13. (i) (ii) 1,
258 1. eipo( eipo S eipo(i) (ii) eipo 253
259 3. (i) UBS AG
260 (ii) A C
261 4. eipo (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix) (x) 256
262 (xi) (xii) (xiii) (xiv) (xv) (xvi) (i) (ii) S S 902(h)(3) (xvii) (xviii) eipo (xix) (i) (ii) 5. eipo eipo eipo 257
263 eipoeipo eipo eipo( 24 eipo eipo eipo eipo E eipo eipowww.eipo.com.hk eipo
264 ( (i) (ii) 259
265 40342E 260
266 1,0001,000 (1) (1) (1) (1) (1) (1) 261
267 E 7. eipoeipo eipo (i) (ii) 262
268 8. eipo 9. eipo 1,000 1,
269 (852)
270 12. (i) eipo 40342E (ii) eipo (iii) 265
271 (iv) eipo 50%
272 (i) (ii) (i) 1,000, ,000,000 (ii) 1,000,
273 1,000,000 (iii) eipo 1,000, ,000,
274 (iv) (
275 270
276 1,001, ,000, Pioneer Medident (SE Asia) Pte. Ltd Pioneer Medident ,000, ,000,000 4,000, I-1
277 # ,800, ,000,000 60% # A 2 Pioneer Medident I-2
278 (i)a 16(ii) (iii) 117,814, A 2 I-3
279 A I-4
280 A , , , , , (404,557) (522,129) (651,978) (299,265) (388,097) , , , , , ,453 15,944 26,604 15,073 42, ,922 3,682 (3,347) (7,091) (63,811) (68,652) (92,087) (41,375) (47,740) (7,440) (15,565) (18,333) (28,670) (11,681) (13,596) (4,976) (5,490) (9,435) (4,805) (3,820) (1,160) , , ,839 87, , (21,805) (26,081) (21,122) (9,194) (13,842) ,077 97, ,717 78, , (62) (3,243) 3,122 (62) (2,627) 547 3, ,077 96, ,090 78, , ,435 95, ,369 78, , ,642 1,337 (652) (343) (1,419) 75,077 97, ,717 78, , ,435 95, ,742 78, , ,642 1,337 (652) (343) (1,419) 75,077 96, ,090 78, , I-5
281 ,373 12,481 11,312 10, ,512 7,063 6, ,479 2,427 2,375 2, ,502 15,855 15, , ,216 17, ,876 14, ,721 5,015 6,331 5,525 26,085 29,488 61,579 82, , , , , ,323 2, , , , , , ,221 2, , , , , ,470 5,300 11, ,336 51,356 59,559 96, , , , , , , , , , ,077 9,894 3,823 2, , , , , ,548 1,952 1,162 3, ,909 2,797 3,223 3, , , , ,728 1,043, , , ,246 (76,639) , , ,825 6, , , , ,057 (189) , , ,057 6, , (421) , , ,825 5, , , ,825 6,136 I-6
282 , , ,286 I-7
283 b a ,435 28,372 23, ,784 9, , ,435 70,435 4,642 75, ,919 (7,919) e (33,774) (33,774) (2,226) (36,000) ,435 36,291 52, ,445 11, , ,675 95,675 1,337 97, (62) (62) (62) (62) 95,675 95,613 1,337 96, ,200 1, ,411 (9,411) e (87,774) (87,774) (2,226) (90,000) c ,565 5,256 10,821 (10,821) ,000 (62) 45,702 56, , , , ,369 (652) 185, (3,243) (2,627) (2,627) ,369 (3,243) 183,742 (652) 183, ,756 (6,756) d (16,190) (16,190) (16,190) e (147,600) (147,600) (147,600) , ,458 88,478 (3,243) 212, , , ,499 (1,419) 111, ,122 3,396 3, ,499 3, ,895 (1,419) 114, ,286 6,286 6,286 f (165,141) (165,141) (165,141) g ,685 (45,000) 4,315 e (163,000) (163,000) (163,000) ,286 (50,646) 828 7,458 42,292 (121) 6,097 (421) 5,676 I-8
284 b a ,000 (62) 45,702 56, , , ,448 78,448 (343) 78, ,448 78,995 (343) 78, d (16,190) (16,190) (16,190) e (53,100) (53,100) (53,100) , ,702 81, , ,450 (a) (b) (c) (d) (e) 36,000,00090,000,000147,600,00053,100, ,000,000 (f) 2 117,814,00047,327, (g) I-9
285 , , ,839 87, , ,976 5,490 9,435 4,805 3, (5,827) (7,455) (14,428) (9,355) (6,772) ,534 1,801 1, , (25) (21) (62) , ,526 3, ,548 1,952 1, (1,803) 3,476 1,049. 1, , (417) (1,080) (499) (557) (133) (6,359) ,816 2,910 3,454 1,785 1, , , ,565 87, , ,668 (135,319) (56,331) 37,518 (4,819) (40,733) (30,120) (42,586) (20,572) (17,975) 72,167 46,869 (14,680) 63, (6,199) (10,712) , , (2,181) (3,548) (1,952) (1,952) (1,162) ,052 (16,052) ,133 3, ,832 65, , (25,938) (19,548) (29,385) (16,252) (14,533) (4,990) (5,300) (8,904) (6,724) (3,707) (418) (1,785) (838) (123) ,205 (21,777) 120,758 41, , ,764 5,254 11,927 7,969 6, (25,687) (25,000) (1,500) (8,000) ,687 25,460 1,500 8, (15,714) (1,339) (1,927) (757) (144) (6,284) (20,117) (2,780) (11,709) (4,695) , , ,409 84, , ,606 3,470 5,300 5,300 11, (143,312) (289,409) (294,726) (134,429) (312,618) (3,470) (5,300) (11,862) ,912 (147,341) (27,498) (41,643) (25,729) , , , , , (191,519) (142,877) (338,011) (103,973) (244,353) , (16,190) (16,190) , (1,300) , (36,000) (90,000) (147,600) (53,100) (136,980) (84,642) 106,334 (85,082) 2,694 (97,574) ,475 (62,784) 8,178 2,778 36, , ,336 51,356 51,356 59, (196) ,336 51,356 59,559 54,743 96,141 I-10
286 Elgin Avenue, George Town, Grand Cayman KY1-9005, Cayman Islands1000 Pioneer Pharma (BVI) LimitedPioneer BVI 2. (i) (ii) (iii) Pioneer BVI Pioneer BVI Pioneer BVI Pioneer BVI Pioneer BVI 99 Pioneer BVI 5,000,0005,000,0001 I-11
287 1,001,0001,001,0006,286,000 (iv) (v) (vi) (vii) (viii) 1,000,000 50,210,000 35% 70%19,990,000 70% 20% 10% (i) (ii) (iii)210,000 7,743,60047,404,000 60% Pioneer Medident 60% I-12
288 16,190, I-13
289 I-14
290 I-15
291 I-16
292 I-17
293 I-18
294 I-19
295 I-20
296 6 I-21
297 25 I-22
298 I-23
299 5. 4 I-24
300 78,195,00097,055,000122,127, ,590,000424,000543, ,000324, ,582,000242,632, ,862,000299,696, ,000 1,203,0001,276,000859, I-25
301 1,909,0002,797,0003,223,0003,685, (a) ,221 2, ,216 17, , , , , ,548 1,952 1,162 3, , , ,696 1,006,368 (b) (i) I-26
302 , ,987 1,204 44, ,661 64,623 67,081 49, , ,659 15,792 24,987 9, ,512 1, , ,405 27,508 47, ,320 80,482 92,254 64,576 5% 5% 5% ,062 1,711 2, % 232,391,000256,224, ,335,000 5% I-27
303 8,715,0009,608,000 12,575,000 (ii) ,000543,000128,000 (iii) 70% 9,473,000 9,908,00070% I-28
304 12,716,0006,786,000 70% 6,200,00011,926,000 70% 2,100,00011,926,000 6% 7% 5% 5% 24% 24% 17% 19% I-29
305 76,639, ,899, % ,897 1, , , , , , , , , , , ,804 3,548 3,548 I-30
306 % , , , , , , , , , , , , , , , ,952 1,952 % ,566 2, , , , , , , ,978 71, , , , , , , ,044 1,162 1,162 I-31
307 % , , , , , , , , , , ,922 31,096 30, , , ,012,816 1,006, ,161 24,161 1, ,414 2,414 2,414 (c) I-32
308 1) 26a 3,548,000 1,952,000 1,162,000 2) 26b) 2,221, ,000 3) 20 14,216,000 17,053,000 4a) 26c) a 2,088,000 4b) 26c) a 1,476,000 5) 26d) b 2,414,000 I-33
309 a5% 220,000 b 1% 612, ,614 4, (2,526) (2,526) ,088 2, (3,564) (2,414) (5,978) ,476 1, (2,414) (2,414) I-34
310 , , , , , ,456 3,499 37, , , , , , (a) (b) I-35
311 , , , (76,667) (327,890) (404,557) ,882 72, , , (63,811) (15,565) (4,976) , , , , (89,387) (432,742) (522,129) ,050 90, , , , (68,652) (18,333) (5,490) ,093 I-36
312 , , , (121,173) (530,805) (651,978) , , , , , (92,087) (28,670) (9,435) , , , , (50,375) (248,890) (299,265) ,508 47, , , (3,347) (41,375) (11,681) (4,805) , , , , (93,883) (294,214) (388,097) ,374 56, , , (7,091) (47,740) (7,440) (13,596) (3,820) (1,160) ,922 I-37
313 , , , , , ,222 65,579 94,383 45,426 57, ,592 36,938 61,683 25,812 36, ,567 38,939 17,954 26, ,116 21,756 8,720 12, ,402 4,855 12,466 14,171 Zenotec ,896 2, , , , ,319 24,849 24,268 12, ,014 15,034 26,729 15, ,000 18,494 31,617 8,683 40, , , , , ,330 90% 95% 10% ,937 7,269 11,383 5,337 35, ,827 7,455 14,428 9,355 6, ,453 15,944 26,604 15,073 42,536 I-38
314 , , (13) (480) (135) (108) (260) (1,668).. (1,367) 3,399 (5,212) (3,804) (5,978) , ,922 3,682 (3,347) (7,091) ,976 5,490 9,435 4,805 3, ,741 3,065 5,410 2,035 3, ,708 10,708 19,122 8,751 13, ,207 14,528 25,153 11,093 16, , a ,440 b (417) ,534 1,801 1, , , , , , , (334) (594) (775) (381) (410) I-39
315 a b ,963 26,855 24,978 12,794 12, ,963 27,375 24,978 12,794 12, (2,540) (2,540) (2,158) (1,294) (2,002) (1,746) ,805 26,081 21,122 9,194 13, % Pioneer Medident 17% 25% 22% 24% 25% 25% [2011]1415% [2008]62[2011]52 40% 9% 2,540,000 40% I-40
316 , , ,839 87, ,922 25% ,221 30,773 51,710 21,825 31, , , (905) (1,590) , (190) (2,848) (3,815) (29,688) (12,012) (22,763) (251) (126) (2,540) (2,540) ,805 26,081 21,122 9,194 13, , ,377,843 I-41
317 I-42
318 ,000, ,072 1,517 1, , ,250 1,714 2,041 1,017 1, I-43
319 , ,466 2,493 15,565 9, , , (103) (103) , ,526 2,669 16,801 9, ,529 1, (251) (147) (398) , ,561 4,051 18,330 9, (176) (464) (640) , ,918 3,758 18,447 9, ,315 5,771 9, (10,761) (445) (3,366) (14,572) (9,447) , ,771 12, , ,910 1, , (16) (16) , ,117 4,428 1, , (241) (139) (380) , ,105 1,682 5,849 2, , (167) (361) (528) , ,338 2,100 7,135 2, , (3,557) (307) (2,229) (6,093) (3,057) , , , ,651 1,552 12,373 7, , ,456 2,369 12,481 7, , ,580 1,658 11,312 6, , ,771 10,855 5% 20% 20% I-44
320 2,169, ,479 2,427 2,375 2,349 2,531 2,479 2,427 2, , , , , , , , ,622 I-45
321 19. QualiMed Innovative Medizinprodukte GmbHQualiMed AMG International GmbH 19,2841 Q3 Medical Devices LimitedQ Q3 12.8% QualiMed ,254 Q3 Q3 3.5% ,284 1 Q Q3 22.1% Q3 21.4% Q3 21.4% , , , ,691 I-46
322 , (9,105) (9,105) Q ,144 Q , (1,360) Q , ,400 4,842 1,323 2, ,800 5,824 1,997 4, ,200 11,968 2,879 9,935 8,400 22,634 6,199 16, (2,201) (5,723).. 6,199 16,911 6,199 16, ,323 2, ,876 14, I-47
323 17 16% 10% 16% I-48
324 , (221) 229 (170) 372 1,948 2, ,018 3, (28) 21 1, (516) (256) 1, , ,762 5, (74) (93) 2,637 (390) (141) 63 2, (19) (30) (21) (616) (686) , ,209 6, (46) (2,648) 42 (195) 135 1,950 (747) (53) (6) (59) , ,344 1,950 5, ,0002,711,0006,901, ,289 1, , , ,711 6,901 I-49
325 10% 40,191, , ,700,000 48,220,000105,493,00090,307, ,000247,00073, ,000 I-50
326 ,619 97, , , (424) (543) (107) (324) 78,195 97, , , ,632 37,826 55,988 36, , , , , ,841 2,269 4,531 6, (260) (122) (136) (46) 119, , , , ,454 3,655 6,156 6, ,042 7,223 3,864 5, ,148 7,567 1, , , , ,159 16,052, ,191 83, , , ,855 12,670 15,080 31, ,321 3, ,195 97, , , ,830 22,029 33,173 12, ,802 15,016 18,466 19, ,656 2, ,693 1,643 36,632 37,826 55,988 36,772 I-51
327 11,004,000 13,500,000 14,042,000 19,847, ,855 12,670 12,702 18, ,315 1, ,004 13,500 14,042 19, , (1,080) (499) (557) (133) , , a. I-52
328 30 16,052, (a) ,548 1,952 1,162 (c) ,476 (d) ,414 3,548 1,952 1,162 3,890 (b) , (c) ,088 2,221 2,618 (a) 3,066, ,782, ,678, , , , ,830, ,446, , ,223, , , , , , , , , , , , , I-53
329 480, , , , , , , , , , , , , , , , , , , ,385, , , , ,508, , ,465, , ,869, , , ,613, , ,081, , ,216, , , ,216, ,378, ,224, , ,445, ,691, ,492, ,275, ,466, , ,969, ,834, I-54
330 (b) 320, % 2.16% 670, % 2.16% 5,869, % 2.16% 3,613, % 1.94% 3,081, % 1.98% 162, % 1.98% 2,216, % 1.98% 495, % 1.98% 154, % 1.98% 4,216, % 2.01% 613, % 2.01% 1,378, % 2.05% 3,224, % 2.20% 483, % 2.20% 2,445, % 2.85% 3,691, % 2.95% 2,492, % 2.70% 3,275, % 2.50% 926, % 2.40% 3,969, % 2.40% 1,466, % 1.80% (c) NovaBay Pharmaceuticals, Inc.NovaBay2,000,000 (a) NovaBay (b)1.50 NovaBay 2,500,000 15,700,000 NovaBay NovaBay 3 I-55
331 % 76.33% 75.28% % 0.14% 0.09% 0.09% % 0.00% 0.00% 0.00% , , ,588 (238,840) ,339,841 2,273,748 2,088,490 (1,475,719) NovaBay (d) Q3 Q Q3 Q3 Q3 Q3 Q3 Q3 10% 12750,000 1,344, I-56
332 10% 15.75% % 0.36% 0.50% 0.01% 0.50% 0.01% 0.50% 2.25% 2.50% 2.95% 3.50% 3.30% 4.35% 3.50% 4.35% 2 133,417, % 0.40% 0.44% 0.35% , ,131 23, , I-57
333 , , , , ,576 3,393 2, ,593 2,897 15,841 4, ,744 5,201 2,166 12, ,289 10,453 9,094 17, ,779 1,919 2, , ,038 4,731 5, , , ,580 8,248 6,609 4, , , , , , , , , ,866 44,451 48,326 66, , , , , ,784 13, , , , , , ,276 5,287 I-58
334 29. (a) (1) (2) Covex, S.A. (3) (4) (5) 2 (b) (1) (2) (c) Covex, S.A ,933 16,235 50,000 15,000 3,000 I-59
335 (d) ,687 25,000 8,000 (i) ,646 34,646 (ii) (400) (ii) (60) Covex, S.A. (iii) (9,268) (iv) (209,166) (ii) (400) (ii) (60) (v) (4,455) (460) (460) (222,889) (i) (ii) 400,000 60,000 (iii) 90 Covex, S.A. (iv) 92,652, ,514,000 2 (v) I-60
336 (e) ,531 2,021 2,340 1,151 1, ,764 2,307 2,630 1,299 1, , , , , , , , , ,784 25, , , , , ,052 17,205 14, , , , , , , , , , , , ,000 30,894 I-61
337 % 3.36% 3.28% 6.70% 1.26% 6.90% 1.20% 6.90% % 2.05% 0.96% 2.38% 2.21% 1.8% , , , , , , (2,523) , , (2,022) , , (3,028) , , (1,402) ,685 I-62
338 ,000,000 5,000,000 31, ,100,000 1,001,000 6, ,100,100 1,001,001 6, ,000, Pioneer BVI0.01 Pioneer BVI99 Pioneer BVI 100,100,000 Pioneer BVI % 4,642 1,616 11, (421) , (421) I-63
339 ,814,000 47,327,000 29(d) ,646 29(d) (92,652) (58,006) (59) , (106) (6,390) (8,479) (1,083) 10,679 (47,327) , , , , ,000775,000410,000 I-64
340 ,064 2,412 1,539 1,429 3,170 2, % 2,800,0002,800, (2,800) , ,843,000 3,166,000 5,503,000 2,078,000 3,455, , ,000 I-65
341 B. 975,000 C. i) Pioneer Pharma (BVI) 399,899,9005 ii) 2,500,000, ,000,000 30,000,000 D. I-66
342 A (9,525) 1,025,290 1,015, (9,525) 1,255,108 1,245, (1) (2) 333,334, (3) 2 1,333,334,000 (4) (5) II-1
343 B. II-1 II (7) 3420 II-2
344 (a) (b) (c) 4.29(1) II-3
345 1. (a) (b) 27(2) 2. (a) (i) (ii) III-1
346 (iii) (iv) (v) (vi) III-2
347 (aa) (bb) (cc) (dd) (ee) (5%) (1) (2) (ff) III-3
348 (vii) (viii) III-4
349 (aa) (bb) (cc) (dd) (ee) (ff) (ix) III-5
350 (x) (xi) (b) (c) (i) (ii) (iii) (iv) (v) (d) III-6
351 (e) 14 III-7
352 30 (f) (g) (h) 15 (i) (i) (ii) (a) (b)(c) III-8
353 (d) (e) (f) (g) (j) (k) (l) III-9
354 (m) (n) 21 III-10
355 (o) (i) (ii) (a) (b) III-11
356 (p) 2.50 (q) 14 III-12
357 (r) 3(f) (s) (i) (ii) III-13
358 (t) (i) 12(ii) 12 (iii) 12 (u) 3. (a) (b) (a) (b) III-14
359 (c)37(d)(e) (c) (d) III-15
360 (e) (f) (a)(b) (c) (a)(b) (c)(d) III-16
361 (g) (h) (i)(ii) (iii) (i) (j) 6 (i) (ii) 20 (k) III-17
362 (l) (m) (n) (a) (b)(c) (d) III-18
363 21 (o) (p) III-19
364 (q) (r) 4. Walkers III-20
365 A XI ,000,000500,000, Walkers Nominees Limited Pioneer Pharma (BVI) 0.01 Pioneer Pharma (BVI)99 Pioneer Pharma (BVI) 100,100,000 Pioneer Pharma (BVI) 399,899,900 5,000,000500,000, ,500,000,000 5,000,000500,000, ,000,0003,000,000, ,333,340 1,333,334,0001,666,666,000 IV-1
366 3. (a) (b) (c) 2,500,000,000 5,000, ,000, ,000,000 3,000,000, (1) (2) (i) (ii) (d) (e) 5,000,000 Pioneer Pharma (BVI) 500,000,000 (d) 20% IV-2
367 (f) (g) 10% (e) (f) (e) 10% (e) (f) (g) (1) (2) (3) (1) IV-3
368 100%50,210, %19,690,000 70%300, %10% (2) 7,743,600 IV-4
369 Pioneer Medident Pioneer Medident Pioneer Medident 6 Asian Strategic Alliance Partners Pioneer Medident 4 Asian Strategic Alliance Partners 199,99479,996 Pioneer Medident 199,99479, ,000,0001 Asian Strategic Alliance Partners Grand Hill Technology 600,000200, , ,000,0001 1,001,000 1,001,000 3,998, IV-5
370 (i) (a) 10% (b) (c) 10% 30 5% (d) IV-6
371 (e) (aa) (bb) (f) 30 (g) (ii) (iii) 1,333,334, ,333,400 IV-7
372 26 B. 1. (i) (ii) NovaBay 2,000,000 (I) NovaBay (II)1.50 NovaBay 2,500,000 QualiMed700,000 Q3 (iii) Eric Mangiardi Angelika Baldewein Günter Dei ner Gerd Schober Martina Schmitt Manfred Gülcher Thomas Nissl Clemens Meyer Kobbe-Kobbe Mitchtech SA Q (iv) (v) 210,000 NovaBay IV-8
373 3 (vi) Q3 QualiMed AMG Dei ner-schober Gesellschaft bürgerlichen Rechts Ni l-gülcher Gesellschaft bürgerlichen Rechts eventions LLC Dei ner & Schober Haus- und Grundstücksverwaltung GbR QualiMed AMG Q3 Q (vii) (viii) (ix) (x) (xi) (xii) (xiii) (xiv) Q3 Q3 Q3 Q3 Angelika Baldewein12,856 Q3 Q3 500,000 Gerhard Schober12,856 Q3 Q3 500,000 Günter Deißner12,856 Q3 Q3 500,000 QualiMed Q3 QualiMed Q3 7,743, % 50,210,000 35% 19,690,000 IV-9
374 (xv) (xvi) 70% 300,000 D. 1. (xvii) (xviii) Covex (xix) 2. 17, ,478, , ,750.1 IV-10
375 2 C ,040 1, ,000 2, , , ,600 Blk 998 Toa Payoh North #03 10 Singapore ,000 C. 1. XV XV (i) (1) 1,000,000, % (1) Pioneer Pharma (BVI) 48.5% 48.5% IV-11
376 (ii) (1) Pioneer Pharma (BVI) 9,700,000 97% (2) Q3 1, % Q3 9, % (1) 9,700,000 Pioneer Pharma (BVI) 4,850,000 4,850,000 Pioneer Pharma (BVI) (2) Q (a) XV (b) (c) IV-12
377 D. 1. B , Walkers Frost & Sullivan 16 7 IV-13
378 6. Pioneer Pharma (BVI) Intertrust Corporate Services (BVI) Limited 171 Main Street, Road Town Tortola VG 1110 British Virgin Islands 50,000,000 (1) (1) 7. 44A44B 8. 32L 4 E. (a) (i) (ii) (iii) (iv) (v) (b) D. 5. IV-14
379 (c) (d) D. 5. Intertrust Corporate Services (Cayman) Limited IV-15
380 (a) (b) D. 5. (c) B. 1. (d) (a) (b) (c) (d) (e) Walkers (f) (g) B. 1. (h) D. 5. (i) (j) Frost & Sullivan V-1
381
全唐诗50
... 1... 1... 2... 2... 3... 3... 3... 4... 4... 5... 5... 6... 6... 6... 7... 7... 7... 8... 8... 8... 9 I II... 9...10...10...10...11...11...11...12...12...12...13...14...14...15...15...16...16...16...17,...17...18...18...19...19...19
30,000,000 75,000,000 75,000, (i) (ii) (iii) (iv)
30,000,000 75,000,000 75,000,000 24 (i) (ii) (iii) (iv) # * 1,800,000 1,800,000 15% 3,400,000 3,400,000 15% 4,200,000 4,200,000 10% 8,600,000 8,600,000 10% 12,600,000 12,600,000 88% 10% 16,000,000 16,000,000
(b)
1. (a) (b) (c) 22 85155 (i) (ii) 2200 5 35% 20% 500 3,000 3015 50% 30 (i) (ii) (iii) (iii) 30% QFII 15% H (20)(5) (iv) (i)(ii) (iii) (iv) (v) 10 30 (vi) 5% (vii) (1) (1) 25%(1) (viii) (ix) 10% 20 45 20
JINTIAN PHARMACEUTICAL GROUP LIMITED 500,000,000400,000,000 100,000,000 50,000,000 450,000,000350,000,000 100,000,000 4.23 1% 0.003%0.005% 0.001 2211
105;0(5 7/(94(*,
Microsoft Word - COC HKROO App I _Chi_ Jan2012.doc
附 錄 I 目 錄 項 目 貨 品 描 述 頁 數 (I) 活 動 物 ; 動 物 1 (II) 植 物 2 (III) 動 物 或 植 物 脂 肪 及 油 及 其 分 化 後 剩 餘 的 ; 經 處 理 可 食 的 脂 肪 ; 動 物 或 植 物 蠟 2 (IV) 經 配 製 的 食 品 ; 飲 料 酒 及 醋 ; 煙 草 及 製 成 的 煙 草 代 替 品 2 (V) 礦 產 5 (VI) 化
China Xinhua Education Group Limited 400,000,000 40,000, ,000, % % 0.005% C
CHINA XINHUA EDUCATION GROUP LIMITED 中國新華教育集團有限公司 於開曼群島註冊成立之有限公司 股份代號 02779 全球發售 獨家保薦人 聯席全球協調人 聯席賬簿管理人及聯席牽頭經辦人 China Xinhua Education Group Limited 400,000,000 40,000,000 360,000,000 3.69 1.0% 0.0027%
智力测试故事
II 980.00 ... 1... 1... 1... 2... 2... 2... 3... 3... 3... 3... 4... 4... 5... 5... 6... 6... 7... 7... 8... 8... 8... 9... 9...10...10...10 I II...11...11...11...12...13...13...13...14...14...14...15...15...15...16...16...17...17...18...18...19...19...19...19...20...20...21...21...21
RDEC-RES
RDEC-RES-089-005 RDEC-RES-089-005 VI I II III 6 IV 7 3 V VI VII VIII IX X XI XII XIII XIV XV XVI XVII XVIII XIX XX 1 2 3 4 5 6 7 8 躰 ( 9 10 躰 11 12 躰 1 13 14 躰 15 16 躰 17 18 19 1 20 21 22 2 23 24 25 26
Microsoft Word - John_Ch_1202
新 约 圣 经 伴 读 约 翰 福 音 目 录 说 明..I 序 言 : 圣 经 中 神 圣 启 示 的 三 层.II 按 时 分 粮 的 原 则..VIII 纲 目 XI 第 一 章..1 第 二 章 13 第 三 章 25 第 四 章 37 第 五 章 49 第 六 章 61 第 七 章 73 第 八 章 85 第 九 章 97 第 十 章..109 第 十 一 章..121 第 十 二 章..133
I. 1-2 II. 3 III. 4 IV. 5 V. 5 VI. 5 VII. 5 VIII. 6-9 IX. 9 X XI XII. 12 XIII. 13 XIV XV XVI. 16
125-0834I/1405/GH I. 1-2 II. 3 III. 4 IV. 5 V. 5 VI. 5 VII. 5 VIII. 6-9 IX. 9 X. 10-11 XI. 11-12 XII. 12 XIII. 13 XIV. 14-15 XV. 15-16 XVI. 16 I. * ++p ++ p ++ ++ * ++p ++ ++ ++p 1 2 ++ ++ ++ ++ ++ I.
<4D F736F F D20BB4FAA46BFA4B2C4A447B4C15F D313038A67E5FBAEEA658B56FAE69B9EAAC49A4E8AED72D5FAED6A977A5BB5F >
行 政 院 104 年 11 月 2 日 院 臺 綜 字 第 1040149345A 號 函 核 定 臺 東 縣 第 二 期 (105-108 年 ) 綜 合 發 展 實 施 方 案 ( 核 定 本 ) 臺 東 縣 政 府 中 華 民 國 1 0 4 年 1 1 月 臺 東 縣 第 二 期 (105-108 年 ) 綜 合 發 展 實 施 方 案 ( 核 定 本 ) 目 錄 第 一 章 前 言...
施 的 年 度 維 修 工 程 已 於 4 月 15 日 完 成, 並 於 4 月 16 日 重 新 開 放 給 市 民 使 用 ii. 天 水 圍 游 泳 池 的 年 度 維 修 工 程 已 於 3 月 31 日 完 成, 並 於 4 月 1 日 重 新 開 放 給 市 民 使 用 iii. 元
地 委 會 文 件 2016/ 第 25 號 ( 於 6.5.2016 會 議 討 論 ) 康 樂 及 文 化 事 務 署 在 元 朗 區 內 舉 辦 的 康 樂 體 育 活 動 及 設 施 管 理 綜 合 匯 報 (2016 年 5 月 號 報 告 ) 目 的 本 文 件 旨 在 向 各 委 員 匯 報 康 樂 及 文 化 事 務 署 ( 康 文 署 ) 於 2016 年 2 月 至 5 月 在
,, 17 075 200,, 170, 1, 40, 4 000, 5,,,, 100 600, 862,, 100, 2 /5,, 1 /5, 1 2,, 1 /5,,, 1 /2,, 800,,,,,,, 300,,,,,, 4 300,,,,, ,,,,,,,,,,, 2003 9 3 3. 22 24 4. 26 30 2 33 33 1. 34 61 1. 1 37 63 1. 2 44
<D6D0B9FAB9C5CAB757512E6D7073>
黄 河 文 明 的 历 史 变 迁 丛 书 编 委 会 学 术 顾 问 李 学 勤 朱 绍 侯 姚 瀛 艇 郝 本 性 晁 福 林 王 巍 主 任 李 小 建 苗 长 虹 副 主 任 覃 成 林 高 有 鹏 牛 建 强 刘 东 勋 主 编 李 玉 洁 编 委 苗 书 梅 程 遂 营 王 蕴 智 张 新 斌 郑 慧 生 涂 白 奎 袁 俊 杰 薛 瑞 泽 陈 朝 云 孔 学 郑 贞 富 陈 彩 琴 石
Q TECHNOLOGY (GROUP) COMPANY LIMITED 250,000,000 25,000, ,000, % %0.005% C %0.0027%0.005%
Q TECHNOLOGY (GROUP) COMPANY LIMITED 250,000,000 25,000,000 225,000,000 3.601.0% 0.0027%0.005% 0.01 1478 32 342C 3.602.79 3.601.0%0.0027%0.005% 2.793.60 www.hkexnews.hkqtechglobal.com (1) www.eipo.com.hkeipo
(2) (2) (3) ei
COGOBUY GROUP 343,800,000 34,380,000 309,420,000 4.48 1% 0.003%0.005% 0.0000001 400 342C UBS AG 2014 7 112014 7 17 4.48 3.20 2014 7 17 144A S 2014 7 8 (2).......................... 2014 7 11..................
t01hkpo
Da Sen Holdings Group Limited 180,000,000 18,000,000 162,000,000 0.901.0% 0.0027%0.005% 0.01 1580 342C 0.900.60 0.60 0.90 S (1) www.eipo.com.hkeipo (2)... (3)...... (4)... eipo......... (a) (b)www.msdscn.com
<4D6963726F736F667420576F7264202D20B6ABD0CBD6A4C8AFB9C9B7DDD3D0CFDEB9ABCBBECAD7B4CEB9ABBFAAB7A2D0D0B9C9C6B1D5D0B9C9CBB5C3F7CAE9A3A8C9EAB1A8B8E5202032303134C4EA33D4C23131C8D5B1A8CBCDA3A92E646F63>
东 兴 证 券 股 份 有 限 公 司 ( 住 所 : 北 京 市 西 城 区 金 融 大 街 5 号 ( 新 盛 大 厦 )12 15 层 ) 首 次 公 开 发 行 股 票 招 股 说 明 书 ( 申 报 稿 ) 保 荐 人 ( 主 承 销 商 ) 瑞 银 证 券 有 限 责 任 公 司 住 所 : 北 京 市 西 城 区 金 融 大 街 7 号 英 蓝 国 际 金 融 中 心 12 层 15
財 務 委 員 會 審 核 2014 至 2015 年 度 開 支 預 算 的 報 告 2014 年 7 月
香 港 特 別 行 政 區 立 法 會 財 務 委 員 會 審 核 2014 至 2015 年 度 開 支 預 算 的 報 告 2014 年 7 月 財 務 委 員 會 審 核 2014 至 2015 年 度 開 支 預 算 的 報 告 2014 年 7 月 章 節 目 錄 頁 數 I 序 言 1-2 II 公 務 員 事 務 3-9 III 司 法 及 法 律 事 務 10-19 IV 財 經 事
Asiaray Media Group Limited 110,000,000 11,000,000 99,000, % % 0.005% C % %0.005%
Asiaray Media Group Limited 110,000,000 11,000,000 99,000,000 7.02 1% 0.0027% 0.005% 0.10 1993 342C 2015 1 7 2015 1 13 7.025.85 7.02 1% 0.0027%0.005% 7.02 2015 1 13 8 S 2014 12 31 www.asiaray.com www.hkexnews.hk
奇闻怪录
... 1... 1... 2... 3... 3... 4... 4... 5... 5... 6... 8... 9... 10... 10... 11... 11... 13... 13... 14... 14... 15... 16... 17... 21 I ... 22... 23... 23... 24... 25... 25... 26... 27... 28... 29 UFO...
Shanghai Haohai Biological Technology Co., Ltd. * 40,000,000H 36,000,000H 4,000,000H H59.001% %0.005% H C H
Shanghai Haohai Biological Technology Co., Ltd. * 40,000,000H 36,000,000H 4,000,000H H59.001% 0.0027%0.005% H1.00 6826 32 342C H 2015423 201542859.00 48.502015428 59.00 1%0.0027%0.005%59.00 (www.hkexnews.hk)
t08phip
Zhou Hei Ya International Holdings Company Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) 1933 Zhou Hei Ya International Holdings Company Limited [ ] [ ] [ ] [ ][ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ][ ]
Winning Tower Group Holdings Limited 350,000, ,000,000 70,000, ,000, ,000,000 70,000,000 35,000, % % 0.005% 0.01
Winning Tower Group Holdings Limited 8362 Winning Tower Group Holdings Limited 350,000,000 280,000,000 70,000,000 315,000,000 245,000,000 70,000,000 35,000,000 0.22 0.18 1% 0.0027% 0.005% 0.01 8362 32
VICON HOLDINGS LIMITED 100,000,000 10,000,000 90,000, % % 0.005% C % % 0.005% 1.2
VICON HOLDINGS LIMITED 100,000,000 10,000,000 90,000,000 1.201% 0.0027% 0.005% 0.01 3878 32 342C 1.21.0 1.21%0.0027%0.005%1.2 (1) www.vicon.com.hkwww.hkexnews.hk... www.eipo.com.hkeipo (2)... (3)......
EAGLE LEGEND ASIA LIMITED 936 51% ............................................................ 1...................................................... 4................................... I-1.................................
............................................................ 1... 6... 29............................................ 39............................................ 52 i (i) (ii) 50% 1 1,000,000 50% 305.HK
Microsoft Word - ????:?????????????
春 秋 航 空 股 份 有 限 公 司 ( 住 所 : 上 海 市 长 宁 区 定 西 路 1558 号 乙 ) 首 次 公 开 发 行 股 票 招 股 意 向 书 保 荐 人 ( 主 承 销 商 ) 瑞 银 证 券 有 限 责 任 公 司 住 所 : 北 京 市 西 城 区 金 融 大 街 7 号 英 蓝 国 际 金 融 中 心 12 层 15 层 春 秋 航 空 股 份 有 限 公 司 首 次
untitled
CHONG KIN GROUP HOLDINGS LIMITED 1609 CHONG KIN GROUP HOLDINGS LIMITED 191,200,000 113,400,000 77,800,000 19,120,000 172,080,000 94,280,000 77,800,000 0.70 0.66 1% 0.0027% 0.005% 0.01 1609 342C 0.700.66
《小王子》 （法）圣埃克苏佩里 原著
小 王 子 ( 法 ) 圣 埃 克 苏 佩 里 原 著 献 给 莱 翁 维 尔 特 请 孩 子 们 原 谅 我 把 这 本 书 献 给 了 一 个 大 人 我 有 一 条 正 当 的 理 由 : 这 个 大 人 是 我 在 世 界 上 最 好 的 朋 友 我 另 有 一 条 理 由 : 这 个 大 人 什 么 都 懂 ; 即 使 儿 童 读 物 也 懂 我 还 有 第 三 条 理 由 ; 这 个 大
(1) eipo (2)... (3) eipo... (4)... (3)... (5)... (1)... (2) (3) (1)(2) (6)...
NNK Group Limited 100,000,000 10,000,000 90,000,000 1.76 1.0%0.0027% 0.005% 0.01 3773 32 342C 1.761.00 1.761.0%0.0027%0.005% 1.76 1.001.76 www.hkexnews.hkwww.nnk.com.hk S (1) www.eipo.com.hk eipo (2)...
2015年廉政公署民意調查
報 告 摘 要 2015 年 廉 政 公 署 周 年 民 意 調 查 背 景 1.1 為 了 掌 握 香 港 市 民 對 貪 污 問 題 和 廉 政 公 署 工 作 的 看 法, 廉 政 公 署 在 1992 至 2009 年 期 間, 每 年 均 透 過 電 話 訪 問 進 行 公 眾 民 意 調 查 為 更 深 入 了 解 公 眾 對 貪 污 問 題 的 看 法 及 關 注, 以 制 訂 適 切
7Road Holdings Limited 666,680,000 66,668, ,012, % %0.005% C
797 7Road Holdings Limited 666,680,000 66,668,000 600,012,000 2.22 1.50 1% 0.0027%0.005% 0.000005 797 342C 2.22 1.50 1.50 2.22 www.hkexnews.hkwww.7road.com S (1).......................... www.eipo.com.hkeipo
山东出版传媒招股说明书
( 山 东 省 济 南 市 英 雄 山 路 189 号 ) 首 次 公 开 发 行 股 票 ( 申 报 稿 ) 保 荐 机 构 ( 主 承 销 商 ) 中 银 国 际 证 券 有 限 责 任 公 司 ( 上 海 市 浦 东 银 城 中 路 200 号 中 银 大 厦 39 层 ) 首 次 公 开 发 行 股 票 ( 一 ) 发 行 股 票 类 型 : 人 民 币 普 通 股 (A 股 ) ( 二 )
<4D6963726F736F667420576F7264202D20CDF2B4EFB5E7D3B0D4BACFDFB9C9B7DDD3D0CFDEB9ABCBBECAD7B4CEB9ABBFAAB7A2D0D0B9C9C6B1D5D0B9C9CBB5C3F7CAE9A3A8C9EAB1A8B8E532303134C4EA34D4C23137C8D5B1A8CBCDA3A92E646F63>
( 住 所 : 北 京 市 朝 阳 区 建 国 路 93 号 万 达 广 场 B 座 11 层 ) 首 次 公 开 发 行 A 股 股 票 ( 申 报 稿 ) 保 荐 人 ( 主 承 销 商 ) 住 所 : 上 海 市 浦 东 银 城 中 路 200 号 中 银 大 厦 39 层 万 达 电 影 院 线 股 份 有 限 公 司 首 次 公 开 发 行 股 票 本 公 司 的 发 行 申 请 尚 未
(i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix) (x) (i) (ii)(iii) (iv) (v)
1948 12 1 1986 1 1995 1995 3 1995 5 2003 4 2003 12 2015 82015 10 1 2004 2 1 (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix) (x) (i) (ii)(iii) (iv) (v) (vi) (vii)(viii) (ix) (x) (xi) 2013 8 15 (i) (ii) (iii)
-i-
-i- -ii- -iii- -iv- -v- -vi- -vii- -viii- -ix- -x- -xi- -xii- 1-1 1-2 1-3 1-4 1-5 1-6 1-7 1-8 1-9 1-10 1-11 1-12 1-13 1-14 1-15 1-16 1-17 1-18 1-19 1-20 1-21 2-1 2-2 2-3 2-4 2-5 2-6 2-7 2-8 2-9 2-10 2-11
Microsoft Word - 强迫性活动一览表.docx
1 1 - / 2 - / 3 - / 4 - / 5 - I. 1. / 2. / 3. 4. 5. 6. 7. 8. 9 10 11. 12. 2 13. 14. 15. 16. 17. 18. 19. 20 21. 22 23. 24. / / 25. 26. 27. 28. 29. 30. 31. II. 1. 2 3. 4 3 5. 6 7 8. 9 10 11 12 13 14. 15.
1 2 6 8 15 36 48 55 58 65 67 74 76 150 152 1 3 1 2 4 2 2001 2000 1999 12 31 12 31 12 31 304,347 322,932 231,047 14,018 16,154 5,665 (i) 0.162 0.193 0.082 (ii) 0.165 0.227 0.082 (iii) 10.08 13.37 6.47 0.688
- 1 - ( ) ( ) ( )
: 2 2868 4679 [email protected] www.edlb.gov.hk/edb/chi/papers/cdoc/ - 1 - ( ) 2. 3. 4. 2004 ( ) 60 5. ( ) - 2-6. ( 483 ) 7. ( 32 ) ( 448 ) 1995 ( ) 1 8. 1 ( ) 128 129 130 - 3-9. (i) (ii) (iii)
目 錄 頁 次 釋 義......................................................... 1 董 事 會 函 件..................................................... 3 言.............
此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問 應諮詢 閣下的股票經紀 其他持牌證 券商 銀行經理 律師 專業會計師或其他專業顧問 閣下如已售出或轉讓名下所有金嗓子控股集團有限公司的股份 應立即將本通函連同隨附的代 表委任表格送交買主或承讓人 或經手買賣的銀行 股票經紀或其他代理人 以便轉交買主或 承讓人 香 交易及結算所有限公司及香 聯合交易所有限公司對本通函的內容概不負責 對其準確性
[] Honma Golf Limited 133,991,000 13,400,000 120,591,000 10.981.0% 0.0027%0.005% 0.0000025 6858 32 342C 10.98 8.4610.981.0% 0.0027%0.005%10.98 144A144A S (1) www.eipo.com.hkeipo (2)... (3)...... eipo...
目 錄 頁 碼 定 義... I 董 事 會 函 件... 1 附 錄 I 財 務 信 息... I-1 附 錄 II 一 般 信 息... II-1 1
此 乃 要 件 請 即 處 理 閣 下 對 本 通 函 任 何 方 面 或 對 應 採 取 之 行 動 如 有 任 何 疑 問, 應 諮 詢 閣 下 之 註 冊 證 券 商 銀 行 經 理 律 師 專 業 會 計 師 或 其 他 專 業 顧 問 閣 下 如 已 售 出 或 轉 讓 名 下 全 部 康 哲 藥 業 控 股 有 限 公 司 股 份, 應 立 即 將 本 通 函 送 交 買 主 或 承 讓
2004 1 SINOPEC YANGZI PETROCHEMICAL CO., LTD. YPC 2 3 777 025 57787735 57787739 025 57787755 [email protected] 4 1 777 210061 210048 http://www.ypc.com.cn/ [email protected] 5 http://www.cninfo.com.cn 6 000866
对联故事
980.00 ... 1... 1... 2... 3... 3... 4... 4... 5... 5... 6... 7... 7... 8... 9...10...10...11...12...13...13...14...15...15...16...17 I II...18...18...19...19...20...21...21...22...22...23...24...25...25...26...26...27...28...29...29...30...30...31...32...32...33...34...34...35
(1)... (2) (3)... (4)... elpo (5) (www.cms.net.cn) (www.hkex.com.hk)... (6)...
CHINA MEDICAL SYSTEM HOLDINGS LIMITED * 200,000,000170,000,000 30,000,000 20,000,000 180,000,000150,000,000 30,000,000 5.06 1% 0.004%0.005% 0.005 867 32 342C 5.063.60 5.06 1% 0.004%0.005% 3.60 5.06 www.hkex.com.hk
08封面封底
2008311 WANT WANT CHINA HOLDINGS LIMITED 2,717,882,000397,582,000 2,320,300,000 2,446,094,000125,794,000 2,320,300,000 271,788,000 4.101% 0.004%0.005% 0.02 0151 342C 2008 31420083244.103.00 2008324 8 (1)
書冊1.indb
2 3 5 9 11 25 32 35 36 37 38 39 77 168-200 28 2811 183 22 18 7 701 www.chinabillion.net 274 1 50 25 Cricket Square, Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands 2014 2 2011 2011 2014
untitled
KML Technology Group Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) 32 [ ] KML Technology Group Limited [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ][] [ ] [ ] 1%0.0027% 0.005% [ ] 0.01 [ ] [ ] [ ]
A8 A8 New Media Group Limited A8 800 (1) (2) (3) 6 20 21 22 34 1002 A823 EGM-1 EGM-2 183 17 1712-1716 48 ........................................................... 1.....................................................
Microsoft Word - Entry-Level Occupational Competencies for TCM in Canada200910_ch _2_.doc
草 稿 致 省 級 管 理 單 位 之 推 薦 書 二 零 零 九 年 十 月 十 七 日 加 拿 大 中 醫 管 理 局 聯 盟 All rights reserved 序 言 加 拿 大 中 醫 管 理 局 聯 盟, 於 二 零 零 八 年 一 月 至 二 零 零 九 年 十 月 間, 擬 定 傳 統 中 醫 執 業 之 基 礎 文 件 由 臨 床 經 驗 豐 富 之 中 醫 師 教 育 者 及
CT ENVIRONMENTAL GROUP LIMITED 340,000,000 34,000, ,000, % 0.005% 0.003% C %0.003%0.005% 1.98 S
CT ENVIRONMENTAL GROUP LIMITED 340,000,000 34,000,000 306,000,000 1.98 1% 0.005% 0.003% 0.10 1363 32 342C 1.981.48 1.981%0.003%0.005% 1.98 S (1) www.eipo.com.hk eipo (2)... (3)...... (4)... eipo......
Microsoft Word - Final Chi-Report _PlanD-KlnEast_V7_ES_.doc
九 龍 東 商 業 的 統 計 調 查 - 行 政 摘 要 - 2011 年 5 月 統 計 圖 行 政 摘 要...1 圖 I: 在 不 同 地 區 及 樓 宇 類 別 的 數 目 及 比 例...9 圖 II: 影 響 選 擇 地 點 的 因 素 的 重 要 程 度 對 比 就 現 時 所 在 地 點 各 項 因 素 的 滿 意 程 度...20 圖 III: 影 響 選 擇 樓 宇 的 因 素
[] Mastermind Group Holdings Limited [] [] [][] [] [] [] [] [] [] [][] 1% %0.005% 0.01 [] [] [] [] [] [] [][]32 342C [] [][] []
![[] Mastermind Group Holdings Limited [] [] [][] [] [] [] [] [] [] [][] 1% %0.005% 0.01 [] [] [] [] [] [] [][]32 342C [] [][] []](/thumbs/91/106251375.jpg "[] Mastermind Group Holdings Limited [] [] [][] [] [] [] [] [] [] [][] 1% %0.005% 0.01 [] [] [] [] [] [] [][]32 342C [] [][] []")
Mastermind Group Holdings Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) 1933 (j) (k) [] Mastermind Group Holdings Limited [] [] [][] [] [] [] [] [] [] [][] 1% 0.0027%0.005% 0.01 [] [] [] [] [] [] [][]32
全唐诗28
... 1... 1... 1... 2... 2... 2... 3... 3... 4... 4... 4... 5... 5... 5... 5... 6... 6... 6... 6... 7... 7... 7... 7... 8... 8 I II... 8... 9... 9... 9...10...10...10...11...11...11...11...12...12...12...13...13...13...14...14...14...15...15...15...16...16...16...17...17
「香港中學文言文課程的設計與教學」單元設計範本
1. 2. 3. (1) (6) ( 21-52 ) (7) (12) (13) (16) (17) (20) (21) (24) (25) (31) (32) (58) 1 2 2007-2018 7 () 3 (1070) (1019-1086) 4 () () () () 5 () () 6 21 1. 2. 3. 1. 2. 3. 4. 5. 6. 7. 8. 9. ( ) 7 1. 2.
歡 迎 您 成 為 滙 豐 銀 聯 雙 幣 信 用 卡 持 卡 人 滙 豐 銀 聯 雙 幣 信 用 卡 同 時 兼 備 港 幣 及 人 民 幣 戶 口, 讓 您 的 中 港 消 費 均 可 以 當 地 貨 幣 結 算, 靈 活 方 便 此 外, 您 更 可 憑 卡 於 全 球 近 400 萬 家 特
歡 迎 您 成 為 滙 豐 銀 聯 雙 幣 信 用 卡 持 卡 人 滙 豐 銀 聯 雙 幣 信 用 卡 同 時 兼 備 港 幣 及 人 民 幣 戶 口, 讓 您 的 中 港 消 費 均 可 以 當 地 貨 幣 結 算, 靈 活 方 便 此 外, 您 更 可 憑 卡 於 全 球 近 400 萬 家 特 約 商 戶 簽 賬, 尊 享 種 種 購 物 飲 食 及 娛 樂 消 費 優 惠 如 需 查 詢 滙
(i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix) (x) (xi) 60.99%39.01%
48.55% 1998 19986 30%20086 2009 2009 200 (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix) (x) (xi) 60.99%39.01% 200820092010 772 928960200820092010 1512928 201 1. 20091222(2009)7267 20042008 16,980,954.02
HUAXI HOLDINGS COMPANY LIMITED : 75,000,000 60,000,000 15,000,000 : 67,500,000 : 7,500,000 : %0.003% 0.005% : 0.01 : C
HUAXI HOLDINGS COMPANY LIMITED 華禧控股有限公司 HUAXI HOLDINGS COMPANY LIMITED 華禧控股有限公司 於開曼群島註冊成立的有限公司 股份代號 1689 股份發售 HUAXI HOLDINGS COMPANY LIMITED 華禧控股有限公司 保薦人 獨家賬簿管理人及獨家牽頭經辦人 海通國際資本有限公司 海通國際證券有限公司 HUAXI HOLDINGS
[ ] China Art Financial Holdings Limited [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [0.01] [ ] [ ] [ ] [ ] [ ] C [ ] [ ] [ ] [ ] [ ] [ ] [ ] [
![[ ] China Art Financial Holdings Limited [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [0.01] [ ] [ ] [ ] [ ] [ ] C [ ] [ ] [ ] [ ] [ ] [ ] [ ] [](/thumbs/43/23140299.jpg "[ ] China Art Financial Holdings Limited [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [0.01] [ ] [ ] [ ] [ ] [ ] C [ ] [ ] [ ] [ ] [ ] [ ] [ ] [")
China Art Financial Holdings Limited (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) 1933 [ ] China Art Financial Holdings Limited [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [0.01] [ ] [ ] [ ] [ ] [ ] 32
untitled
ROYAL DELUXE HOLDINGS LIMITED 3789 ROYAL DELUXE HOLDINGS LIMITED 300,000,000216,000,000 84,000,000 30,000,0003,000,000 270,000,000186,000,000 84,000,000 0.671% 0.0027%0.005% 0.01 3789 32 342C 0.67 0.53
年报正文7.PDF
2000 ...3...4...5...9...12...15...25...25...33...70...70 - 3 - Baoshan Iron & Steel Co., Ltd. 26647000 26646999 ir@ baosteel.com 201900 http://www.baosteel.com http://www.sse.com.cn 600019-4 - 4,378,138,887.87
* 3,000,000, ,000,000 2,700,000, %0.004% 0.005% C %0.004%0.005% (i)144a (ii) 501(a) (iii)s *
* 3,000,000,000 300,000,000 2,700,000,000 1.71 1%0.004% 0.005% 0.01 1387 32 342C 1.711.40 1.711%0.004%0.005% (i)144a (ii) 501(a) (iii)s903904 * (1) (2)................. (3)................ eipowww.eipo.com.hk
TEN PAO GROUP HOLDINGS LIMITED 250,000,000 25,000, ,000, % %0.005% C S
TEN PAO GROUP HOLDINGS LIMITED TEN PAO GROUP HOLDINGS LIMITED 250,000,000 25,000,000 225,000,000 0.80 1% 0.0027%0.005% 0.01 1979 32 342C S 0.80 0.55 www.hkexnews.hkwww.tenpao.com (1) www.hkexnews.hk www.tenpao.com